Physician profile
Thomas P Atkinson
NPI 1508853631
$52,801.86
in general payments reported to CMS, 2019-2025
17 companies · $13K in 2025
The $13K reported for 2025 was more than what 90% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,198 · 2020: $15K · 2021: $7,125 · 2023: $8,334 · 2024: $8,097 · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $27K · Travel and Lodging: $1,827 · Food and Beverage: $495.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $26,728.34 |
| Travel and Lodging | $1,827.22 |
| Food and Beverage | $494.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharming Healthcare, INC. | $11,078.99 | 2020-2025 | Joenja |
| Glaxosmithkline, LLC. | $9,726.81 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $8,484.67 | 2019-2024 | |
| Regeneron Pharmaceuticals, INC. | $8,005.50 | 2023 | Eylea Hd |
| Aquestive Therapeutics, INC. | $6,097.27 | 2025 | |
| Csl Behring | $4,690.00 | 2021 | |
| Horizon Therapeutics Plc | $4,180.00 | 2020-2021 | |
| Abbvie INC. | $115.73 | 2019 | |
| Lilly USA, LLC | $96.91 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $91.63 | 2019-2024 | Dupixent |
| Glaukos Corporation | $88.22 | 2023 | Photrexa Cross-Linking Kit |
| Sobi, INC | $65.26 | 2025 | |
| Pfizer INC. | $31.39 | 2020-2021 | |
| Grifols USA, LLC | $22.69 | 2020 | |
| Shire North American Group INC | $13.70 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $13.09 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Atkinson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.